The acquisition has enabled Indicia to provide a highly specialised manufacturing area dedicated to the filling of dermal filler in syringes
Photo as seen on Bio-Steril website showing final packaging
Indicia Production, a CMO specialising in the manufacture of ready-to use microbiological media and sterile pharmaceutical ingredients, has acquired Bio-Steril. France-based Bio-Steril specialises in the formulation and fill-finish of medical devices for cosmetic and medical uses.
The financial terms of the transaction have not been disclosed.
This acquisition allows Indicia to extend its manufacturing capabilities and open new market areas, such as dermo-aesthetics, ophthalmology and rheumatology. It also means that Indicia can now provide a highly specialised manufacturing area dedicated to the filling of dermal filler in syringes.
Created in June 2004, Bio-Steril is a CMO specialised in the production of sterile medical devices and cosmetics liquids and gels. Based on customer’s either bulk or in-house formulated products, Bio-Steril produces sterile pre-filled syringes, vials and glassware.
Manufacturing at Bio-Steril is achieved in cleanroom of ISO Class 7 and ISO Class 8 standards, while filling is done under ISO Class 5 conditions. A wide variety of final packaging is available and the company is certified ISO13485.
“I am very happy with this new acquisition, which perfectly complements our current offer,” said Stephane Legastelois, chairman and CEO of Indicia Production. “Bio-Steril’s know-how will be very valuable to our customers.”
“Indicia Production is a well-known company and we are very pleased to join its ranks,” said René Trehorel, chairman of Bio-Steril. “We offer very specific know-how in sterilisation and production of sterile medical devices which will enhance Indicia’s global offer.” Indicia Production currently offers three product families:
As a recognised player in the field of OEM manufacturing of sterile ingredients, Indicia conforms to GMP and ISO 13485 environments, both required for the manufacturing of pharmaceutical excipients and medical devices.
The consolidated company will operate with 85 employees. Its combined turnover for 2019 is estimated to reach €12.5 million (US$13.9m).